Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab

By afschroeder • August 20, 2025

Cheon J, Ryoo BY, Chon HJ, Kim HD, Ryu MH, Kim KP, Kang B, Finn RS, Chan SL, Yoo C. Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab. Liver Cancer. 2025 Jan 21;14(4):446-455. doi: 10.1159/000543666. PMID: 40831890; PMCID: PMC12360742.

Tags: Atezolizumab, Bevacizumab, Hematology/Oncology, Hepatocellular carcinoma, Publications, regorafenib, Tyrosine kinase inhibitor

PKC inhibitors reveal PKC isoforms involved in HIV latency reversal and immunomodulation

Zaikos TD, Pham V, Chou TC, Moran JA, Turner SR, Yu BH, Hourani R, Ranjan A, Zack JA, Wender PA, Marsden MD. PKC inhibitors reveal[...]

Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy

Carlson SG, Puliafito BR, Kawai K, Senaratne TN, Lee TD, Lin T, Timmerman J, Larson SM. Impact of clonal hematopoiesis of indeterminate potential on treatment[...]

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson[...]